| Pharmaceutical Information |
| Drug Name |
Gemifloxacin mesylate |
| Drug ID |
BADD_D01014 |
| Description |
Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase and topoisomerase IV, which are essential for bacterial growth. |
| Indications and Usage |
For the treatment of bacterial infection caused by susceptible strains such as S. pneumoniae, H. influenzae, H. parainfluenzae, or M. catarrhalis, S. pneumoniae (including multi-drug resistant strains [MDRSP]), M. pneumoniae, C. pneumoniae, or K. pneumoniae. |
| Marketing Status |
approved; investigational |
| ATC Code |
J01MA15 |
| DrugBank ID |
DB01155
|
| KEGG ID |
D02471
|
| MeSH ID |
D000077735
|
| PubChem ID |
9588170
|
| TTD Drug ID |
D0VR7W
|
| NDC Product Code |
68801-320; 50370-0021 |
| UNII |
X4S9F8RL01
|
| Synonyms |
Gemifloxacin | 7-(3-aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid | Factive | Gemifloxacin Mesylate | SB-265805 | SB265805 | SB 265805 | LB 20304 | LB-20304 | LB20304 |
|
| Chemical Information |
| Molecular Formula |
C19H24FN5O7S |
| CAS Registry Number |
210353-53-0 |
| SMILES |
CON=C1CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F.CS(=O)(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
